Organogenesis Holdings Inc. Third Quarter of Fiscal Year 2026 Earnings Conference Call - ORGANOGENESIS HOLDINGS INC

Financial Performance:

• Total net product revenue for Q3 2026 was $45.5 million, representing a 70% year-over-year decline; however, revenue increased 6% sequentially from Q2 2026, driven by a 6% rise in advanced wound care and a 10% rise in surgical/sports medicine sales.
• Advanced wound care revenue was $38.2 million (down 73% YoY), while surgical and sports medicine revenue was $7.3 million (down 19% YoY).
• Gross profit was $23.6 million, yielding a gross margin of 52%, down significantly from 76% in the prior year period.
• Operating expenses decreased 42% year-over-year to $75 million (non-GAAP operating expenses were $53 million, down 44%), driven by $34.7 million reduction in SG&A and $5.3 million reduction in R&D.
• The company reported a GAAP net loss of $32.7 billion (notably likely a transcription error for $32.7 million given context of other figures) compared to net income of $14.5 billion last year; adjusted net loss was $29.3 million versus an adjusted net income of $23.2 million last year.
• Adjusted EBITDA loss was $22.4 million, improved significantly from a $30.1 million loss in the prior year.
• Cash and cash equivalents stood at $26.9 million as of September 30, 2026, down from $94.3 million at year-end 2025, with no outstanding debt.
• Management expects current cash and working capital to fund operations and capital expenditures for at least the next 12 months.

Guidance and Future Outlook:

• Full-year 2027 total net revenue is now guided to be between $179 million and $200 million, reflecting a 65% to 68% decline year-over-year, a steeper contraction than the previously anticipated 58% to 62% decline.
• The updated outlook assumes advanced wound care revenue of $151–$171 million, surgical/sports medicine revenue of $26–$27 million, and grant income of $1.9 million.
• Sequential improvement in revenue trends is expected to continue through Q4 2026, with a more measured recovery anticipated in the second half of the year compared to H1.
• Profitability guidance projects a sequential reduction in adjusted EBITDA loss, expecting a >60% reduction in the second half versus the first half, and potentially positive adjusted EBITDA in Q4 2026 at the high end of the range.
• Cost reduction initiatives, including restructurings and efficiency measures, are projected to reduce operating expenses by approximately $45 million annually ($32 million restructuring-related).

Business Segments and Product Lines:

• Organogenesis gained over 30% market share versus Q1 2026, growing at a rate double that of major competitors, driven by a broad-based increase in volume across its portfolio including AlloDerm (Applegraph), PurePly AM, Affinity, and NuShield.
• The PUREPLY AM product received validation from a published PIVOTAL trial (PREPARE) showing statistically significant improvements in wound closure for diabetic foot ulcers, supporting future coverage policy inclusion.
• The MNUVIC (Amnuvix) program for knee osteoarthritis is currently under BLA review; the FDA accepted the filing in June and completed a pre-licensure inspection in Q3.
• The FDA identified 18 remediation items at the Norwood facility, with the PDUFA date extended to a target of September 30, 2027 (previously April 2027) to allow for completion of facility upgrades.
• The Amnuvix remediation is estimated to cost $8 million total ($4 million incremental cost, $4 million accelerated capital spending), with $2 million expected in 2026 and the remainder in 2027.

Market and Competitive Landscape:

• The market is in a "reset" phase following CMS policy changes and coverage policy withdrawals regarding skin substitutes and discarded product rules, resulting in a 70% YoY revenue contraction.
• Competitive dynamics have shifted dramatically: distributor-driven competitors and high-priced amniotic players have been substantially reduced or exited the market, leaving a landscape focused on efficacy and evidence.
• Customers are increasingly prioritizing products with robust clinical evidence and FDA biologic PMA approvals, allowing Organogenesis to outperform industry declines.
• Approximately 20% of Q3 sales were attributed to remaining inventory from competitors who have exited the market, creating a temporary supply glut expected to flush out by year-end 2026.
• Management anticipates the market will settle into a structure with 4-5 major, evidence-backed competitors by the end of 2026 or early 2027, with market expansion potentially returning to double digits.

Risks and Challenges:

• Regulatory uncertainty persists regarding CMS "discarded product" rules, causing confusion among clinicians and patients regarding the reimbursement and usage of products like AlloDerm (Applegraph).
• The BLA for Amnuvix faces a timeline delay due to facility remediation requirements, extending the commercial launch window to late 2027.
• The market transition involves a significant revenue contraction in 2026, with the company facing a challenging environment of inventory overhang from exiting competitors.
• Potential for delayed or uncertain future coverage policies if clinical data and regulatory clarity do not sufficiently address payer concerns regarding living cell-based therapies.

Management Commentary and Tone:

• Management expressed strong optimism regarding the long-term future, describing the company as emerging from the market reset as a leader in regenerative medicine with the "best evidence-base portfolio."
• The tone was confident and constructive, emphasizing that the market has "bottomed out" and is transitioning from price-driven competition to efficacy-driven demand.
• Management highlighted a strategic pivot to prioritize clinical evidence and scientific validation as the primary currency for market credibility.
• CFO Dave Francisco and CEO Gary Cohen emphasized that the significant cost-cutting measures and operational restructuring have positioned the company to reach positive adjusted EBITDA in Q4 2026.

Analyst Questions and Answers:

• Ryan Zimmerman (U.S. Bank Corp. BTIG): Asked about the recovery curve and potential price/volume dynamics.
  • Answer: Management stated the market has bottomed out, with recovery expected to be driven by the clearing of excess competitor inventory (expected by year-end) and clarifying confusion around FDA policies. Volume and price are expected to stabilize by Q1 2027.
  • Answer: Regarding Q4 positive adjusted EBITDA, management clarified this is achievable on the high end of the guidance range due to $45 million in annualized cost savings, including an additional $8.5 million in COGS savings and $40 million in SG&A reductions.
• Ravi Misra (Truist Securities): Asked about the market trajectory, the "last man standing" scenario, and the financial impact of the Amnuvix delay.
  • Answer: Management confirmed the market bottom and expects a return to double-digit expansion as the market clears, anticipating a consolidation to 4-5 key players.
  • Answer: The Amnuvix delay involves an $8 million total spend ($4 million incremental), with remediation work scheduled to conclude by September 2027.

Other Key Points:

• The company has 40 years of experience in regenerative medicine and holds FDA biologic PMA approvals for multiple products (AlloDerm, Dermagraph, Translite), which serve as a key differentiator against competitors lacking rigorous clinical data.
• Organogenesis is actively engaging with federal policymakers to ensure coverage policies reflect the unique manufacturing and administration of living cell-based biologic therapies.
• The company is investing in expanding its manufacturing capacity at the Smithfield facility to support future growth and efficiency.
• The total number of shares and stock details suggest a potential significant equity dilution event or a specific accounting treatment resulting in the anomalous "$32.7 billion" net loss figure mentioned in the transcript, though the context implies a likely typo for a standard millions figure consistent with other data points.